Cyclic Oligopeptides for IL-13 Binding in Skin Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for skin inflammatory conditions such as atopic dermatitis (AD) and alopecia areata (AA) using IL-13-targeting therapies face limitations, including side effects from topical corticosteroids and the need for injectable biologics like tralokinumab.
Innovation Solution
Development of cyclic oligopeptides that specifically bind to IL-13, offering a topical treatment option with improved skin permeability and reduced biological activities of IL-13 and its receptor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical corticosteroids are used to treat skin inflammatory conditions, then anti-inflammatory effect is improved, but side effects such as skin atrophy, stria, easy bruising, and telangiectasia occur
Solution Approach 1:
The patent extracts the beneficial anti-inflammatory function from IL-13 by developing cyclic oligopeptides that specifically bind to and neutralize IL-13 cytokine. This removes the harmful downstream effects of IL-13 signaling (which cause inflammation) without using corticosteroids that cause skin atrophy and other side effects.
Solution Approach 2:
The cyclic oligopeptides act as intermediary molecules that bind to IL-13 and prevent it from interacting with its receptors. This intermediary approach blocks the harmful inflammatory pathway without directly using corticosteroids that cause the harmful side effects.
2Reliability
If monoclonal antibodies like tralokinumab are used to block IL-13, then IL-13 binding to receptors is prevented, but the treatment requires injection administration
Solution Approach 1:
The patent uses small cyclic oligopeptide molecules instead of large monoclonal antibodies. These smaller peptide molecules have improved skin permeability allowing topical application, whereas large antibodies require injection. The oligopeptides are designed to be stable yet small enough for topical delivery.
Solution Approach 2:
The patent changes the molecular size and structure parameters by using cyclic oligopeptides (small molecules) instead of monoclonal antibodies (large proteins). This parameter change enables topical penetration through the skin barrier while maintaining IL-13 binding capability.
3Ease of operation
If small molecules interfering with IL-13 and receptor interactions are developed, then topical application becomes possible, but the molecules must achieve sufficient binding affinity and specificity
Solution Approach 1:
The patent designs cyclic oligopeptides with composite structures that combine multiple functional elements: specific amino acid sequences for IL-13 binding, cyclic conformation for stability and rigidity, and appropriate molecular size for skin permeation. This composite design achieves both topical applicability and reliable binding.
Solution Approach 2:
The patent uses cyclic (ring-shaped) oligopeptide structures instead of linear peptides. The cyclic conformation provides structural rigidity, defined three-dimensional shape, and improved metabolic stability while maintaining the ability to bind IL-13 with high affinity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cyclic oligopeptides effectively reduce IL-13 biological activities, providing a therapeutic benefit for IL-13-associated skin disorders without the side effects of traditional treatments, and can be administered topically for localized action.
Implementation Method 1
cyclic oligopeptides that specifically bind to IL-13
Data Source
AI summary
The present disclosure relates to cyclic oligopeptides that bind to interleukin-13 (IL-13) which are useful therapeutically in methods of treating or preventing IL-13-associated skin disorders or conditions. The present disclosure also provides methods to treat or prevent IL-13-associated skin disorders or conditions with the IL-13-binding cyclic oligopeptides. The present disclosure further provides methods to produce the IL-13-binding cyclic oligopeptides.